Core Viewpoint - Spectral Medical Inc. is updating its timeline for the Premarket Approval (PMA) submission to the FDA for its hemoadsorption device, PMX, aimed at treating endotoxic septic shock, now expected between late April and mid-May 2026, delayed from the previous target of Q1 2026 [2][4] Group 1: PMA Submission Update - The delay in the PMA submission is due to the need to include complete 12-month mortality data from the Tigris study and to finalize certain non-clinical module items, including human factors engineering testing [2][3] - The company anticipates reporting topline 12-month mortality data in late May or early June 2026, pending additional data analysis [3] Group 2: Product and Market Information - PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream and is guided by the FDA-cleared Endotoxin Activity Assay (EAA) [5] - PMX is already approved for therapeutic use in Japan and Europe, licensed by Health Canada, with over 360,000 units sold globally [6] - Approximately 330,000 patients are diagnosed with septic shock annually in North America, highlighting the market potential for PMX [6] Group 3: Clinical Trial Details - The Tigris Trial is a confirmatory study comparing PMX in addition to standard care against standard care alone, designed as a 2:1 randomized trial involving 150 patients [7]

Core Insights - Spectral Medical Inc. has completed enrollment for its Tigris trial, a Phase III clinical trial evaluating PMX for endotoxic septic shock, with topline results expected in August 2025 [1][2][3] - The company has entered into a promissory note agreement with Vantive for up to US$10 million to support PMX commercialization [1][9] Clinical Development - The Tigris trial has enrolled a total of 157 patients, with 151 evaluable patients and 100 treated with PMX [6] - The data lock for the trial is expected to be completed in approximately 90 days, with topline results anticipated two weeks post-data lock [6] - The company is on track to submit clinical results to the FDA by the end of October 2025 [6] Financial Performance - Revenue for Q1 2025 was $572,000, a decrease of 14% from $668,000 in Q1 2024 [10] - Operating expenses increased significantly to $13,174,000, up 173% from $4,825,000 in the prior year, primarily due to non-cash fair value adjustments [11] - The company reported a loss of $12,605,000 for Q1 2025, compared to a loss of $4,160,000 in Q1 2024 [13] Balance Sheet and Financing - As of March 31, 2025, the company had cash of $1,670,000, down from $2,988,000 at the end of 2024 [14] - The promissory note with Vantive includes a four-year maturity and a payment-in-kind interest rate of 9% [15] Commercialization Activities - The company is collaborating with Vantive on post-approval marketing plans for PMX commercialization [15] - Vantive intends to submit a 510(k) application for its PrisMax System, which is expected to be the primary device used for PMX treatments upon commercial launch [15] Regulatory and Clinical Study Insights - The EDEN study, completed in Q4 2023, showed that patients with endotoxic septic shock had a significantly higher mortality rate of 60% compared to 14.1% for other septic shock patients [6] - The results from the EDEN study will inform discussions with the FDA regarding PMX labeling and the addressable population in the U.S. [6]